Skip to main content

Table 1 Baseline Characteristics of the 11 Patients Enrolled in the Study

From: First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors

Characteristic Patients
n %
Age, years Median (range) 65 (35–79)
Sex Male 8 73
  Female 3 27
ECOG performance status 0 11 100
Cancer types Gastric or gastro-esophageal 6 55
  Colorectal 4 36
  Esophageal 1 9
  Pancreas 1 9
Microsatellite instability status Microsatellite stable 9 82
  Unknown 2 18
Previous treatment line Median (range) 5 (2–11)
Previous anti-PD1/PDL1 Yes 4 36
Metastatic sites Lymph node 8 73
  Lung 5 45
  Liver 4 36
  1. ECOG Eastern Cooperative Oncology Group